Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivanib in Asian patients with advanced HCC
NCT01108705Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- May 2010
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of brivanib in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Started May 2010; status: terminated.
02
Drugs
brivanib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01108705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01108705.